Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.69 |
| ▸ | ITGAV | P06756 | 14/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.69 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 8/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7402263 | 0.90 | ITGB3 (0.67) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7400628 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7403109 | 0.88 | ITGB3 (0.66) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7405155 | 0.87 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL8552844 | 0.87 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7396351 | 0.86 | ITGB3 (0.70) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| Trifluoroacetic Acid SCHEMBL7403084 | 0.85 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7398017 | 0.85 | ITGB3 (0.70) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7405983 | 0.84 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7404155 | 0.84 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |